tbuckley/cabot-search huggingface dataset:
Abstract 4987: Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immuno-oncology treatments
Authors: Suzanne I. Sitnikova, Michelle Morrow, Viia Valge-Archer, Robert W. Wilkinson, Simon J. Dovedi, Matthew J. Robinson
Journal: Cancer Research (2019)

Abstract Immuno-oncology research relies heavily on murine syngeneic tumor models. However, whilst the median age for a cancer diagnosis is 65 years or older, for practical purposes the majority of preclinical studies are conducted in young mice, despite the fact that aging has been shown to have a significant impact on the immune response. Using aged mice bearing CT26 tumors, we analysed how aging impacts the immune composition of the tumor, spleen and tumor-draining lymph nodes by flow cytometry. We found many age-related changes between aged (60-72 weeks old) and young (6-8 weeks old) mice, such as a reduction in the naïve T cell population and a decreased CD8/Treg ratio in aged animals. Profiling of co-inhibitory and co-stimulatory receptor expression levels on immune cells in aged versus young mice also identified altered expression profiles in both the periphery and tumor. We hypothesised that these differences may contribute to impaired anti-cancer immune responses in aged mice. To investigate this, we compared the anti-tumor efficacy of immune checkpoint blockade (PD-L1 and CTLA-4) and T-cell costimulation (OX-40) in aged versus young mice. Our data demonstrate that aged mice retained their capacity to generate effective anti-tumor immune responses, albeit often attenuated when compared to the responses observed in young mice. These differences highlight the potential importance of age-related immunological changes in assessing and refining the translational insights gained from preclinical mouse models. Citation Format: Suzanne I. Sitnikova, Michelle Morrow, Viia Valge-Archer, Robert W. Wilkinson, Simon J. Dovedi, Matthew J. Robinson. Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immuno-oncology treatments [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4987.
CANCER COMMUNICABILITY.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AN UNUSUAL MONSTER DELIVERED BY CESAREAN SECTION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest
Authors: M. Callaham
Journal: JAMA (1992)

<h3>Objective.</h3> —To determine the relative efficacy of high- vs standard-dose catecholamines in initial treatment of prehospital cardiac arrest. <h3>Design.</h3> —Randomized, prospective, double-blind clinical trial. <h3>Setting.</h3> —Prehospital emergency medical system of a major US city. <h3>Patients.</h3> —All adults in nontraumatic cardiac arrest, treated by paramedics, who would receive epinephrine according to American Heart Association advanced cardiac life support guidelines. <h3>Interventions.</h3> —High-dose epinephrine (HDE, 15 mg), high-dose norepinephrine bitartrate (NE, 11 mg), or standard-dose epinephrine (SDE, 1 mg) was blindly substituted for advanced cardiac life support doses of epinephrine. <h3>Main Outcome Measures.</h3> —Restoration of spontaneous circulation in the field, admission to hospital, hospital discharge, and Cerebral Performance Category score. <h3>Results.</h3> —Of 2694 patients with cardiac arrests during the study period, resuscitation was attempted on 1062 patients. Of this total, 816 patients met study criteria and were enrolled. In the entire cardiac arrest population, 63% of the survivors were among the 11% of patients who were defibrillated by first responders. The three drug treatment groups were similar for all independent variables. Thirteen percent of patients receiving HDE regained a pulse in the field vs 8% of those receiving SDE (<i>P</i>=.01), and 18% of HDE patients were admitted to the hospital vs 10% of SDE patients who were admitted to the hospital (<i>P</i>=.02). Similar trends for NE were not significant. There were 18 survivors; 1.7% of HDE patients and 2.6% of NE patients were discharged from the hospital compared with 1.2% of SDE patients, but this was not significant (<i>P</i>=37; β=.38). There was a nonsignificant trend for Cerebral Performance Category scores to be worse for HDE (3.2) and NE patients (3.7) than for SDE patients (2.3) (<i>P</i>=.10; β=.31). No significant complications were identified. High-dose epinephrine did not produce longer hospital or critical care unit stays. <h3>Conclusions.</h3> —High-dose epinephrine significantly improves the rate of return of spontaneous circulation and hospital admission in patients who are in prehospital cardiac arrest without increasing complications. However, the increase in hospital discharge rate is not statistically significant, and no significant trend could be determined for neurological outcome. No benefit of NE compared with HDE was identified. Further study is needed to determine the optimal role of epinephrine in prehospital cardiac arrest. (<i>JAMA</i>. 1992;268:2667-2672)
RESPONSIBILITY IN JOURNALISM.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Atti del Convegno sulla silicosi, Torino, 22-23 febbraio 1941
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bernard Wilkins
Authors: R. Wilkins, S. Mann
Journal: BMJ (2010)

Four patients exposed to isocyanate vapour developed dyspnoea associated with restriction and reduced gas transfer as well as moderate airways obstruction on lung function testing. In one patient bilateral radiographic shadowing was present and an open lung biopsy was performed. The microscopic appearances ranged from acute inflammation to end-stage fibrosis but the centribular accentuation of disease and the presence of areas resembling bronchopulmonary aspergillosis suggested that the process was a hypersensitivity response to inhaled allergen. Challenge tests with albumin and toluene diisocyanate-albumin were carried out in sensitized and control rabbits. The sensitized animals developed extensive lung damage of the type associated with an Arthus reaction. It is suggested that patients exposed to isocyanates may occasionally develop a hypersensitivity pneumonitis rather than the more usual asthmatic syndrome.
Celiac Disease
Authors: Peter H.R. Green, Christophe Cellier
Journal: New England Journal of Medicine (2007)

Celiac disease is a unique autoimmune disorder in which the environmental precipitant, gluten, is known. Originally considered a rare malabsorption syndrome of childhood, celiac disease is now recognized as a common condition that may be diagnosed at any age and that affects many organ systems. This review discusses the pathogenesis, diagnosis, and management of the disease.
Thymus Organogenesis
Authors: Hans-Reimer Rodewald
Journal: Annual Review of Immunology (2008)

The epithelial architecture of the thymus fosters growth, differentiation, and T cell receptor repertoire selection of large numbers of immature T cells that continuously feed the mature peripheral T cell pool. Failure to build or to maintain a proper thymus structure can lead to defects ranging from immunodeficiency to autoimmunity. There has been long-standing interest in unraveling the cellular and molecular basis of thymus organogenesis. Earlier studies gave important morphological clues on thymus development. More recent cell biological and genetic approaches yielded new and conclusive insights regarding the germ layer origin of the epithelium and the composition of the medulla as a mosaic of clonally derived islets. The existence of epithelial progenitors common for cortex and medulla with the capacity for forming functional thymus after birth has been uncovered. In addition to the thymus in the chest, mice can have a cervical thymus that is small, but functional, and produces T cells only after birth. It will be important to elucidate the pathways from putative thymus stem cells to mature thymus epithelial cells, and the properties and regulation of these pathways from ontogeny to thymus involution.
Aye, Aye
Authors: Joseph J. Bellanca
Journal: JAMA (1987)

I have learned many things during my 21-year career in Navy medicine, but the most important lesson has been the necessity for effective<i>two-way</i>communication, not only in medicine but in everything I do in life. You may never have thought of a military order as effective, two-way communication, but it is and physicians have something to learn from it. The traditional Navy procedure for giving orders is an ingenious technique for preventing communication error. Orders are always short and simple in recognition of the beauty of brevity and the eloquence of simplicity. In addition, the receiver is expected to verbally repeat the order to the giver, followed by "Aye, Sir!" or "Aye, Ma'am!" Repeating the order demonstrates that it was heard correctly. Officer of the Deck: "Helmsman, come left to course two-five-zero." Helmsman: "Come left to course two-five-zero, aye, Sir!" The following "Aye, Sir!" has a specific meaning to
Obstetric Patient as Anesthetic Problem
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Active Euthanasia in the Netherlands
Authors: M. A. M. de Wachter
Journal: JAMA (1989)

Active euthanasia in the Netherlands remains a topic for both professional and public debate. However, many aspects of the medical practice of active euthanasia remain unclear, and no figures on the actual incidence of this practice exist. Legally, active euthanasia is a criminal offense, but a pattern of jurisprudence has developed since the first court case in 1973 that has allowed physicians to practice euthanasia under certain strict conditions. Two proposals, one from the Royal Dutch Medical Association and one from a government-appointed state commission, have advised that the current law be changed. While the debate continues, a number of Dutch institutions have developed procedures and policies to enable physicians and health care providers to participate in active euthanasia in an acceptable and controllable manner. However, many Dutch physicians remain uncomfortable with the professional and public tolerance of this practice. (<i>JAMA</i>. 1989;262:3316-3319)
<i>First, You Cry</i>, 25 Years Later
Authors: Barron H. Lerner, Betty Rollin
Journal: Journal of Clinical Oncology (2001)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.11.2967 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11387372 First, You Cry, 25 Years Later Barron H. LernerxBarron H. LernerSearch for articles by this author Betty RollinxBetty RollinSearch for articles by this author Show More From the Department of Medicine, Columbia College of Physicians and Surgeons, New York, NY. https://doi.org/10.1200/JCO.2001.19.11.2967 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyINVITED COMMENTARY01062001I was stunned to read, at the start of Dr Lerner’s insightful piece, about the (sprinkling of) hostile mail I received when First, You Cry was first published. It’s true, but I had forgotten about it in the wave of subsequent mail and telephone calls—and being stopped in the street—expressing the opposite. For 25 years women have told me how much the book meant to them, how much it helped them get through the trauma of breast cancer. In no way did I expect this, or feel deserving of their gratitude. I’m a writer and I simply took advantage of a bad break in life and told as honestly—and, frankly, entertainingly—as I could what it was like when you’re young and breast cancer hits. It never occurred to me that this would be helpful. I now realize the obvious explanation: in reading my book, women felt less alone, not only with their disease but with the accompanying feelings about it. Dr Lerner quotes a very typical letter from the woman with the “crazys.” “I thought I was the only one who [felt this way or that way]” was—and is—the recurring theme of what I call my “me-too mail.”We all try to be brave when something like cancer happens. I wasn’t brave. I think, in a sense, I gave a lot of women “permission” not to be brave, either—and I think my vanity gave them permission to be vain. I think that made them feel better too.Subsequently, of course, you get over it. But, first, you cry. That’s normal. When the book was re-issued, I re-read it and I was surprised at what a fuss I made about that breast. Of course I was young and in a shaky marriage and—this was 1975, remember—I didn’t know anyone else who was missing half her chest. But I have had a new, recent insight: I think focusing on the breast was a way of not focusing on the much scarier fact of cancer. I think my vanity was partly denial. When I was ready to face the fact that I had had—and may still have—a deadly disease, the loss of the breast loomed less large.National Broadcasting Company, IncNew York, NY
Erratum
Journal: BMJ (1904)

The above lotion smarts a. little for an 'hour sometimes, but not to all patients alike; aitera while it soothes the skin.Babies, for example, will cry forhalf an hour afterthe lotion is applied, then fall into a long sleep, the itchiness of the skin being quite removed for several hours by the izal.Patients should keep on using the lotion for a week after all trace of the disease has passed away from their skin.The bottle needs to be well shaken before use.Equal parts of izal and glycerine give no better results and are more sticky.
Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Authors: A. M. Mauer, E. E. W. Cohen, S. J. Wong, M. Kozloff, J. Winegarden, D. M. Gustin, E. E. Vokes
Journal: Journal of Clinical Oncology (2004)

5539 Background: Studies of EGFR inhibitors in SCCHN have demonstrated reproducible activity. Preclinical studies have implicated angiogenesis as a mechanism of resistance to these agents. Furthermore, angiogenesis has been linked with tumor progression and worse outcome in SCCHN. This phase I multi-institutional trial was undertaken to assess the feasibility and toxicity of adding bevacizumab, an anti-VEGF monoclonal antibody to erlotinib, an EGFR tyrosine kinase inhibitor. Methods: Eligible patients were required to have performance status 2 or better, measurable disease, intact organ function, no more than one prior therapy for recurrent/metastatic disease, and no prior EGFR or VEGF based therapy. Escalating doses of bevacizumab (5, 10, and 15 mg/kg IV q3 weeks) were administered with a fixed dose of erlotinib (150 mg PO QD) to consecutive patient cohorts to establish a phase II dose. Plasma VEGF and serum TGF-alpha levels were drawn prior to therapy, after 2 weeks, and after 8 weeks of therapy. Results: 10 patients have been enrolled with 4, 3, and 3 patients in each cohort. Grade 3 toxicity consisted of diarrhea (1 patient), skin rash (1 patient), lymphopenia (1 patient). One patient experienced grade 4 hemorrhage from a tongue tumor after 6 treatment cycles that was felt to be therapy related. Common grade 1/2 toxicities observed included dermatologic (70%), fatigue (70%), and diarrhea (50%). Dose limiting toxicity, as defined by the protocol, was not observed at any dose level. Of 9 patients evaluated after 2 cycles, we have observed 1 PR, 7 SD, and 1 PD. 6 patients have had stable disease for greater than 12 weeks. Conclusions: Administration of bevacizumab 15mg/kg q3 weeks with erlotinib 150mg QD is feasible and well tolerated in recurrent/metastatic SCCHN. Assessment of regimen efficacy is underway in the phase II segment of this trial. Supported by NCI grant # N01-CM-17102. No significant financial relationships to disclose.
Nursing Home Outbreaks of Invasive Group A Streptococcal Infections — Illinois, Kansas, North Carolina, and Texas
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal